Relationship between colorectal cancer glutathione levels and patient survival - Early results

被引:35
作者
Barranco, SC
Perry, RR
Durm, ME
Quraishi, M
Werner, AL
Gregorcyk, SG
Kolm, P
机构
[1] Eastern Virginia Med Sch, Dept Surg, Norfolk, VA 23507 USA
[2] Eastern Virginia Med Sch, Dept Pathol, Norfolk, VA 23507 USA
[3] Quest Biomed Res Ctr, Virginia Beach, VA USA
[4] Pasadena Gen Hosp, Pasadena, TX USA
关键词
glutathione; colorectal cancer; survival; prognostic factors;
D O I
10.1007/BF02236562
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
PURPOSE: Elevated glutathione is a cause of resistance to anticancer agents and x-rays. The purpose of this study was to determine the frequency and clinical significance of glutathione elevation in human colorectal cancer. METHODS: Glutathione levels were measured in 41 colon cancers, 24 rectal cancers, and corresponding normal tissues. The patients were then followed up prospectively for tumor recurrence and survival. Survival was analyzed by the Kaplan-Meir method and Cox proportional hazards regression. RESULTS: Glutathione levels in primary colorectal cancers were significantly higher than in the corresponding: normal tissues. Elevated glutathione levels had a significant negative effect on survival in patients with colorectal cancer, whether based on the mean (P = 0.02) or median (P = 0.04) normal tissue levels. A negative effect of glutathione: levels on survival was apparent in patients with colorectal cancer, whether or not they were treated with postoperative therapy. The larger the ratio of tumor glutathione to normal tissue glutathione, the poc,rer the prognosis. When adjusted fur other covariates, glutathione was still a significant predictor of survival. CONCLUSIONS: An elevated tumor glutathione level at the time of diagnosis appears to confer a poor prognosis in patients with colorectal cancer. Longer-term study using a larger number of patients will he required to confirm these findings, Knowledge of tumor glutathione content may help identify patients requiring more intensive therapy.
引用
收藏
页码:1133 / 1140
页数:8
相关论文
共 28 条
[1]   PHASE-I CLINICAL-TRIAL OF INTRAVENOUS L-BUTHIONINE SULFOXIMINE AND MELPHALAN - AN ATTEMPT AT MODULATION OF GLUTATHIONE [J].
BAILEY, HH ;
MULCAHY, RT ;
TUTSCH, KD ;
ARZOOMANIAN, RZ ;
ALBERTI, D ;
TOMBES, MB ;
WILDING, G ;
POMPLUN, M ;
SPRIGGS, DR .
JOURNAL OF CLINICAL ONCOLOGY, 1994, 12 (01) :194-205
[2]  
BARRANCO CS, 1983, INVESTIGATIONAL NEW, V1, P117
[3]  
BARRANCO SC, 1988, CANCER RES, V48, P2749
[4]  
BARRANCO SC, 1994, CANCER RES, V54, P5351
[5]  
BARRANCO SC, 1972, CANCER RES, V32, P2733
[6]  
BARRANCO SC, 1990, CANCER RES, V50, P3614
[7]  
BARRANCO SC, 1991, INVEST NEW DRUG, V9, P29
[8]   MEMBRANE-MEDIATED DRUG-RESISTANCE AND PHENOTYPIC REVERSION TO NORMAL GROWTH-BEHAVIOR OF CHINESE-HAMSTER CELLS [J].
BIEDLER, JL ;
RIEHM, H ;
PETERSON, RHF ;
SPENGLER, BA .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1975, 55 (03) :671-680
[9]  
BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
[10]   CELLULAR GLUTATHIONE (GSH) AND GLUTATHIONE-S-TRANSFERASE (GST) ACTIVITY IN HUMAN OVARIAN TUMOR-BIOPSIES FOLLOWING EXPOSURE TO ALKYLATING-AGENTS [J].
BRITTEN, RA ;
GREEN, JA ;
WARENIUS, HM .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1992, 24 (03) :527-531